# Post Marketing Study to Evaluate the Two Dose Regimens of Nicardipine Injection in Hypertensive Emergency Patients

> **NCT01872039** · PHASE4 · COMPLETED · sponsor: **Astellas Pharma China, Inc.** · enrollment: 163 (actual)

## Conditions studied

- Hypertension Emergency
- End-organ Damage

## Interventions

- **DRUG:** Perdipine injection

## Key facts

- **NCT ID:** NCT01872039
- **Lead sponsor:** Astellas Pharma China, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-03
- **Primary completion:** 2014-01
- **Final completion:** 2014-01
- **Target enrollment:** 163 (ACTUAL)
- **Last updated:** 2015-11-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01872039

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01872039, "Post Marketing Study to Evaluate the Two Dose Regimens of Nicardipine Injection in Hypertensive Emergency Patients". Retrieved via AI Analytics 2026-08-18 from https://api.ai-analytics.org/clinical/NCT01872039. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*